A type 2 diabetes (T2D) drug recently approved by the Food and Drugs Administration (FDA) has reportedly reduced more than 20 percent of weight in obese individuals by administering the drug once every week.
The SURMOUNT-1 study, a Phase 3 trial led by Yale University researchers testing the efficacy and safety of tirzepatide, found that obese participants who took the drug at a dosage of 15 mg concentration by the 72nd week had a record-breaking weight reduction of 22.5 percent on average.
